Innate Pharma S.A.
IPHA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -75.7% | -10% | 376.2% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 100% | 10.8% | 10.4% | -184.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -371.7% | -3.5% | -21.3% | -356.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -392% | -14.6% | -100.7% | -436% |
| EPS Diluted | -0.61 | -0.09 | -0.73 | -0.57 |
| % Growth | -577.8% | 87.7% | -28.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |